APA (7th ed.) Citation

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W., Li, F., Buijze, M., . . . Mutis, T. (2020). Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica (Roma), 105(2), e80-e83. https://doi.org/10.3324/haematol.2018.213314

Chicago Style (17th ed.) Citation

Holthof, Lisa C., et al. "Preclinical Evidence for an Effective Therapeutic Activity of FL118, a Novel Survivin Inhibitor, in Patients with Relapsed/refractory Multiple Myeloma." Haematologica (Roma) 105, no. 2 (2020): e80-e83. https://doi.org/10.3324/haematol.2018.213314.

MLA (9th ed.) Citation

Holthof, Lisa C., et al. "Preclinical Evidence for an Effective Therapeutic Activity of FL118, a Novel Survivin Inhibitor, in Patients with Relapsed/refractory Multiple Myeloma." Haematologica (Roma), vol. 105, no. 2, 2020, pp. e80-e83, https://doi.org/10.3324/haematol.2018.213314.